Johnson & Johnson, Pfizer, and GSK faced a busy week filled with notable developments across their pharmaceutical pipelines and regulatory actions. The Food and Drug Administration (FDA) granted priority review status to Johnson & Johnson’s (JNJ) biologics license application (BLA) for nipocalimab, a novel antibody targeting generalized myasthenia gravis (gMG), a rare autoimmune disorder. Simultaneously, the FDA requested that Pfizer (PFE) and GSK (GSK) include a new warning on the labels of their Respiratory Syncytial Virus (RSV) vaccines, Abrysvo and Arexvy, respectively, regarding the potential risk of Guillain-Barré syndrome (GBS). This action highlights ongoing vigilance regarding vaccine safety profiles.
The FDA’s decision to require a revised safety statement reflects a broader trend in regulatory oversight of newly approved vaccines. The request for Pfizer and GSK underscored the agency’s commitment to ensuring patient safety, particularly concerning rare neurological complications. The update to the Prescribing Information sections for both Abrysvo and Arexvy indicated a thorough evaluation of the vaccines’ safety profiles and a proactive approach to risk management. Both Abrysvo and Arexvy, approved in May 2023, have become cornerstones of RSV prevention, and these updated safety warnings are intended to provide clinicians with comprehensive information for prescribing decisions.
Johnson & Johnson was also making further strides in oncology with the FDA granting Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody, for the treatment of early Alzheimer’s disease. This designation expedites the development and regulatory review process for drugs targeting Alzheimer’s, reflecting the significant unmet medical need in the area. The company is already engaged in phase IIb studies evaluating posdinemab, alongside another candidate, JNJ-2056, an anti-tau active immunotherapy for treating preclinical Alzheimer’s disease. These initiatives demonstrate JNJ’s sustained investment in innovative treatments for neurodegenerative disorders.
Beyond the Alzheimer’s focus, Johnson & Johnson achieved a significant milestone in its oncology program. The company’s phase III MARIPOSA study evaluating a combination of Rybrevant plus Lazcluze for the first-line treatment of certain patients with EGFR-mutated non-small cell lung cancer (NSCLC) met the final pre-specified secondary endpoint of overall survival. This successful outcome, observed across the MARIPOSA study, led to the approval of Rybrevant plus Lazcluze for the first-line treatment of patients with EGFR-mutated NSCLC in the United States and EU, based on progression-free survival data. This represents a major advancement in treating a prevalent subtype of lung cancer.
Meanwhile, Novo Nordisk (NVO) continued to expand its collaboration with Valo Health, a company leveraging artificial intelligence (AI) for drug discovery. The companies signed an expanded deal, building upon an existing 2023 agreement, to develop up to 20 novel drug programs in obesity, type II diabetes, and cardiovascular disease. This collaboration brings together Valo’s AI-driven approach with Novo Nordisk’s expertise in metabolic disease, targeting a significantly larger portfolio of potential therapies and expanding the previously agreed-upon milestone payments from $2.7 billion to $4.6 billion, alongside an additional $190 million near-term payment. The expansion highlighted the growing trend of combining AI’s computational power with established pharmaceutical companies, potentially accelerating drug development timelines.
Finally, Johnson & Johnson faced a temporary pause in sales of Varipulse, its pulsed field ablation therapy to treat atrial fibrillation, while it investigated four reported cases of neurovascular events. This pause, initiated on January 5th, didn’t impact sales in international markets and demonstrated the company’s commitment to patient safety and thorough investigation of any adverse events. Pfizer (PFE) concluded a deal with SGMO to end its hemophilia treatment program, and Novartis rose the most (3.0%) in the last trading session. Overall, the week presented a dynamic picture of innovation and strategic partnerships across the pharmaceutical landscape.
